DRG Market Assessment reports

The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…

Stargardt disease (STGD) is a monogenic disease characterized by retinal dystrophy and macular degeneration that results in progressive loss of vision. In contrast to many other forms of macular…

The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…

Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…